Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial

Edimar Alcides Bocchi,Luis E Echeverria,Caroline Demacq,Pedro Gabriel Melo de Barros E Silva,Lilian Mazza Barbosa,Lu-May Chiang,Lucas Damiani,Carlos A Morillo,Ruben Kevorkian,Felix Ramires,M Cecilia Bahit,Ariana Ferrari,Adolfo Chavez-Mendoza,Jose Antonio Magaña-Serrano,John J V McMurray,Claudio Gimpelewicz,Renato D Lopes,PARACHUTE-HF Investigators

DOI: https://doi.org/10.1016/j.jchf.2024.05.021

Abstract:Chronic Chagas cardiomyopathy (CCC) has unique pathogenic and clinical features with worse prognosis than other causes of heart failure (HF), despite the fact that patients with CCC are often younger and have fewer comorbidities. Patients with CCC were not adequately represented in any of the landmark HF studies that support current treatment guidelines. PARACHUTE-HF (Prevention And Reduction of Adverse outcomes in Chagasic Heart failUre Trial Evaluation) is an active-controlled, randomized, phase IV trial designed to evaluate the effect of sacubitril/valsartan 200 mg twice daily vs enalapril 10 mg twice daily added to standard of care treatment for HF. The study aims to enroll approximately 900 patients with CCC and reduced ejection fraction at around 100 sites in Latin America. The primary outcome is a hierarchical composite of time from randomization to cardiovascular death, first HF hospitalization, or relative change from baseline to week 12 in NT-proBNP levels. PARACHUTE-HF will provide new data on the treatment of this high-risk population. (Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC [PARACHUTE-HF]; NCT04023227).